Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Atopic Dermatitis

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

J Eur Acad Dermatol Venereol

Augustin M, Tauber M, Sidbury R, Silverberg JI, Papp KA, Thaçi D, De Bruin-Weller MS, Reich A, Peris K, Barber K, Galus R, Kaszuba A, Zirwas M, Nahm WK, Trullenque G, Maintz L, Alpizar S, Son SW, Laquer V, Gold LS, Cheong SY, Ryzhkova A, Drahos A, Ulianov L, Piketty C

doi: 10.1111/jdv.70080

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Atopic Dermatitis

Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers

J Invest Dermatol

Bissonnette R, Saint-Cyr Proulx E, Correa da Rosa J, Estrada Y, Ren H, Nawaz H, Halden P, Stefani-Hunyady D, Popovic K, Volkova A, Smith SH, Guttman-Yassky E

doi: 10.1016/j.jid.2025.10.613

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Br J Dermatol

Gooderham M, Torres T, Imafuku S, Rademaker M, Prajapati VH, Tsianakas A, Murrell DF, Owczarek W, Han Y, Lee WJ, Levy G, Ibrahim N, Moreira A, Shams K

doi: 10.1093/bjd/ljaf236

Psoriasis

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

J Eur Acad Dermatol Venereol

Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group

doi: 10.1111/jdv.70350

Psoriasis

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis

J Eur Acad Dermatol Venereol

Merola JF, Guenther L, Lynde C, Papp KA, Parish LC, Yamauchi P, Cheng S, Amouzadeh H, Deignan C, Jardon S, Chen M, Pinter A

doi: 10.1111/jdv.70110

Atopic Dermatitis

The Risk of Venous Thromboembolism in Atopic Dermatitis: A Population-Based Cohort Study

Br J Dermatol

Ivert LU, Anveden-Berglind I, Gembert K, Eriksson J, Giunta DH, Hägg D, Linder M

doi: 10.1093/bjd/ljaf418

Further Publications Immunology

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study

J Allergy Clin Immunol Pract

Yang X, Wang L, Huang K, Tang W, Berame EJ, Park HS, Hunter G, Jiang W, Wu CC, Min CW, Domek-Zielinska K, Lal H, Molfino NA, Ponnarambil SS, Zhong N

doi: 10.1016/j.jaip.2025.07.046

Related content

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis

The Risk of Venous Thromboembolism in Atopic Dermatitis: A Population-Based Cohort Study

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study